- Home
- RS vs DVA Comparison
RS vs DVA Comparison
Compare RS & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RS
- DVA
- Stock Information
- Founded
- RS 1939
- DVA 1994
- Country
- RS United States
- DVA United States
- Employees
- RS N/A
- DVA N/A
- Industry
- RS Metal Fabrications
- DVA Misc Health and Biotechnology Services
- Sector
- RS Industrials
- DVA Health Care
- Exchange
- RS Nasdaq
- DVA Nasdaq
- Market Cap
- RS 15.5B
- DVA 12.6B
- IPO Year
- RS 1994
- DVA 1995
- Fundamental
- Price
- RS $288.40
- DVA $166.24
- Analyst Decision
- RS Hold
- DVA Hold
- Analyst Count
- RS 5
- DVA 5
- Target Price
- RS $344.00
- DVA $153.40
- AVG Volume (30 Days)
- RS 580.2K
- DVA 654.3K
- Earning Date
- RS 02-13-2025
- DVA 02-11-2025
- Dividend Yield
- RS 1.53%
- DVA N/A
- EPS Growth
- RS N/A
- DVA 41.03
- EPS
- RS 18.25
- DVA 9.24
- Revenue
- RS $14,045,700,000.00
- DVA $12,666,614,000.00
- Revenue This Year
- RS N/A
- DVA $6.18
- Revenue Next Year
- RS $1.63
- DVA $3.58
- P/E Ratio
- RS $15.78
- DVA $17.98
- Revenue Growth
- RS N/A
- DVA 6.34
- 52 Week Low
- RS $256.98
- DVA $103.40
- 52 Week High
- RS $342.20
- DVA $169.52
- Technical
- Relative Strength Index (RSI)
- RS 58.60
- DVA 69.32
- Support Level
- RS $263.32
- DVA $151.10
- Resistance Level
- RS $277.10
- DVA $154.05
- Average True Range (ATR)
- RS 5.72
- DVA 3.44
- MACD
- RS 3.42
- DVA 1.81
- Stochastic Oscillator
- RS 91.78
- DVA 98.58
About RS Reliance Steel & Aluminum Co. (DE)
Reliance Inc is a diversified metal solutions provider and metals service center company. It provides value-added metals processing services and distributes.
About DVA DaVita Inc.
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the us, and treats about 250,000 patients globally each year. Government payers dominate us dialysis reimbursement. DaVita receives about two thirds of us sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of the us patients treated, they represent nearly all of the profits generated by DaVita in the us dialysis business.